Who are mRNA-1283's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): COMIRNATY intramuscular injection, BNT162b2 Pfizer-BioNTech/Comirnaty, Pfizer-COVID-19 Vaccine, COVID-19 mRNA vaccine, Homologous mRNA booster vaccine, Moderna mRNA-1273 COVID-19 vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mrna-1283.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

mRNA-1283 — Competitive Intelligence Brief

mRNA-1283 (mRNA-1283) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Oncology.

marketed mRNA vaccine HPV16 and HPV18 antigens (E6 and E7 proteins) Oncology Biologic Live · refreshed every 30 min

Target snapshot

mRNA-1283 (mRNA-1283) — ModernaTX, Inc.. mRNA-1283 is a self-amplifying mRNA vaccine that encodes human papillomavirus (HPV) antigens to stimulate immune responses against HPV-infected cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
mRNA-1283 TARGET	mRNA-1283	ModernaTX, Inc.	marketed	mRNA vaccine	HPV16 and HPV18 antigens (E6 and E7 proteins)
COMIRNATY intramuscular injection	comirnaty-intramuscular-injection	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
BNT162b2 Pfizer-BioNTech/Comirnaty	BNT162b2 Pfizer-BioNTech/Comirnaty	KK Women's and Children's Hospital	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Pfizer-COVID-19 Vaccine	Pfizer-COVID-19 Vaccine	National Heart, Lung, and Blood Institute (NHLBI)	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
COVID-19 mRNA vaccine	COVID-19 mRNA vaccine	Vaccine Company, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Homologous mRNA booster vaccine	Homologous mRNA booster vaccine	Tan Tock Seng Hospital	marketed	mRNA vaccine
Moderna mRNA-1273 COVID-19 vaccine	Moderna mRNA-1273 COVID-19 vaccine	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

Pfizer · 12 drugs in this class
ModernaTX, Inc. · 11 drugs in this class
BioNTech SE · 5 drugs in this class
Jules Bordet Institute · 5 drugs in this class
Tan Tock Seng Hospital · 2 drugs in this class
Clover Biopharmaceuticals AUS Pty · 1 drug in this class
CanSino Biologics Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). mRNA-1283 — Competitive Intelligence Brief. https://druglandscape.com/ci/mrna-1283. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab